Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.

Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.

Item

http://www.wikidata.org/entity/Q54116999

Q54116999

about

Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.

Item

http://www.wikidata.org/entity/Q54116999

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Anaplastic lymphoma kinase (AL ...... LK-tyrosine Kinase Inhibitors.

@en

type

Item

label

Anaplastic lymphoma kinase (AL ...... LK-tyrosine Kinase Inhibitors.

@en

prefLabel

Anaplastic lymphoma kinase (AL ...... LK-tyrosine Kinase Inhibitors.

@en

P1476

Anaplastic lymphoma kinase (AL ...... ALK-tyrosine Kinase Inhibitors

@en

P2093

Hyunjin Kim

http://www.w3.org/2001/XMLSchema#string

Jongmin Sim

http://www.w3.org/2001/XMLSchema#string

Joungho Han

http://www.w3.org/2001/XMLSchema#string

Yoon La Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Case report: small cell transformation and metastasis to the breast in a patient with lung adenocarcinoma following maintenance treatment with epidermal growth factor receptor tyrosine kinase inhibitors

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases.

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.

Correlation of Histologic Subtypes and Molecular Alterations in Pulmonary Adenocarcinoma: Therapeutic and Prognostic Implications.

P304

e123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3346/JKMS.2018.33.E123

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-04-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29629521

http://www.w3.org/2001/XMLSchema#string

P932

5890087

http://www.w3.org/2001/XMLSchema#string

Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.

about

Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932